Brightine for Cholangiocarcinoma and Pancreatic Cancers
Boehringer Ingelheim is studying BI 907828, an investigational MDM2-p53 antagonist, for advanced biliary tract or pancreatic cancer.
Boehringer Ingelheim is studying BI 907828, an investigational MDM2-p53 antagonist, for advanced biliary tract or pancreatic cancer.
Discover the power of genomic understanding in curing your cancer. Learn about cells, genes, and genomics and your power within Steve Holmes "Improving [...]
Investing in the power of the grassroots community is to invest in the individual and better cancer survival outcomes.
Explore patient empowerment in cancer, emphasizing hope, active participation, & transforming healthcare through Empowered Patient Initiative
Dive into the facts with Steve Holmes author of 'The Empowered Patient' as he explores the delicate balance between the potential risk of cancer seeding and the critical insights gained from biopsies in cholangiocarcinoma. Uncover why, despite the risks, biopsies often hold the key to effective, personalized treatment in the fight against bile duct cancer."
Hypercalcemia in patients with cholangiocarcinoma occurs when there is abnormally high levels of calcium in the blood